By Research Area
Hot products 
-
Mouse Anti-FOXA3 Recombinant Antibody (2A9) (CBMAB-0377-YC)
-
Mouse Anti-DISP2 Monoclonal Antibody (F66A4B1) (CBMAB-1112CQ)
-
Mouse Anti-CASP7 Recombinant Antibody (10-01-62) (CBMAB-C2005-LY)
-
Mouse Anti-CD8 Recombinant Antibody (C1083) (CBMAB-C1083-LY)
-
Mouse Anti-GOLGA2 Recombinant Antibody (2C10) (CBMAB-G0602-LY)
-
Mouse Anti-EPO Recombinant Antibody (CBFYR0196) (CBMAB-R0196-FY)
-
Mouse Anti-ELAVL4 Recombinant Antibody (6B9) (CBMAB-1132-YC)
-
Mouse Anti-ALX1 Recombinant Antibody (96k) (CBMAB-C0616-FY)
-
Mouse Anti-ARSA Recombinant Antibody (CBYC-A799) (CBMAB-A3679-YC)
-
Mouse Anti-ARID3A Antibody (A4) (CBMAB-0128-YC)
-
Mouse Anti-CD164 Recombinant Antibody (CBFYC-0077) (CBMAB-C0086-FY)
-
Mouse Anti-GFP Recombinant Antibody (28) (CBMAB-G3038-LY)
-
Rat Anti-CD63 Recombinant Antibody (7G4.2E8) (CBMAB-C8725-LY)
-
Mouse Anti-ARG1 Recombinant Antibody (CBYCL-103) (CBMAB-L0004-YC)
-
Rabbit Anti-CCN1 Recombinant Antibody (CBWJC-3580) (CBMAB-C4816WJ)
-
Mouse Anti-CCND2 Recombinant Antibody (DCS-3) (CBMAB-G1318-LY)
-
Mouse Anti-G6PD Recombinant Antibody (13B331) (CBMAB-G1553-LY)
-
Mouse Anti-CTNND1 Recombinant Antibody (CBFYC-2414) (CBMAB-C2487-FY)
-
Mouse Anti-F11R Recombinant Antibody (402) (CBMAB-0026-WJ)
-
Mouse Anti-C5b-9 Recombinant Antibody (aE11) (CBMAB-AO138LY)
By Hallmark/Pathway
The progression from neoplastic transformation to metastatic dissemination is governed by the acquisition of specific biological capabilities—the hallmarks of cancer. These phenotypic alterations, ranging from sustained proliferative signaling to the evasion of immune destruction, are underpinned by profound dysregulation within intracellular kinase networks and transcriptional machinery. Contemporary research emphasizes the need to dissect these pathways not in isolation, but as integrated circuits that drive tumor heterogeneity and therapeutic resistance.
Targeting these mechanisms requires tools of exceptional specificity. Whether investigating the "angiogenic switch" mediated by hypoxic gradients or delineating the epithelial-mesenchymal transition (EMT) axis that facilitates invasion, the fidelity of molecular detection is paramount. Our portfolio is systematically organized to address these critical research nodes, offering validated antibodies and assays designed to interrogate cell cycle checkpoints, apoptotic thresholds, vascular remodeling, and the immunosuppressive tumor microenvironment with high-resolution precision.
Browse by Hallmark/Pathway
Select a pathway to explore targets, antibodies, and validation data.
Loading...
Compare
